Aussie Biotech Prana’s COO Diane Angus: An Interview With PharmAsia News (Part 1 of 2)
This article was originally published in The Pink Sheet Daily
Prana’s lead compound, PB2 for Alzheimer’s, recently completed Phase IIa.
You may also be interested in...
Prana COO Diane Angus And Head Of Research Robert Cherny: An Interview With PharmAsia News (part 2 of 2)
Execs talk about Aussie biotech’s unique mechanism of action in neurodegenerative drug development.
Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.